Orchid receives USFDA approvals for Cefadroxil ANDAs

Orchid Chemicals & Pharmaceuticals Ltd has announced that it has received the formal approval from the USFDA for its Cefadroxil 500 mg Capsules and 1 g Tablets ANDAs (Abbreviated New Drug Applications).

The Company would be launching this oral cephalosporin product in the US through its distribution partner, Par Pharma.

With these approval, the Company’s ANDAs approved till date rises to 17. The total number of ANDAs filed till date stands at 31.

Source : Equity Bulls

Keywords